TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02938962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Study: NCT02670772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: TDF 300mg once daily + Placebo 20mg twice daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
Study: NCT02119065

Intervention type: PROCEDURE
Intervention: positron emission tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Intervention: computed tomography
Description: Undergo PET/CT scan
Study: NCT04325724

Intervention type: OTHER
Group type: OTHER
Intervention: General evaluation
Description: Demographic characteristic, psoriasis duration, disease duration, treatments

Intervention type: OTHER
Group type: OTHER
Intervention: General evaluation
Description: Demographic characteristic, psoriasis duration, disease duration, treatments

Intervention type: OTHER
Group type: OTHER
Intervention: General evaluation
Description: Demographic characteristic, psoriasis duration, disease duration, treatments

Intervention type: OTHER
Group type: OTHER
Intervention: General evaluation
Description: Demographic characteristic, psoriasis duration, disease duration, treatments

Intervention type: OTHER
Group type: OTHER
Intervention: Dermatological evaluation
Description: treatment and evaluation

Intervention type: OTHER
Group type: OTHER
Intervention: Dermatological evaluation
Description: treatment and evaluation

Intervention type: OTHER
Group type: OTHER
Intervention: Dermatological evaluation
Description: treatment and evaluation

Intervention type: OTHER
Group type: OTHER
Intervention: Rheumatological evaluation
Description: joints, enthesis, tendons, and other ultrasound abnormalities

Intervention type: OTHER
Group type: OTHER
Intervention: Rheumatological evaluation
Description: joints, enthesis, tendons, and other ultrasound abnormalities

Intervention type: OTHER
Group type: OTHER
Intervention: Rheumatological evaluation
Description: joints, enthesis, tendons, and other ultrasound abnormalities

Intervention type: OTHER
Group type: OTHER
Intervention: Rheumatological evaluation
Description: joints, enthesis, tendons, and other ultrasound abnormalities

Intervention type: OTHER
Group type: OTHER
Intervention: para clinical data
Description: biological data, medical imaging data

Intervention type: OTHER
Group type: OTHER
Intervention: para clinical data
Description: biological data, medical imaging data

Intervention type: OTHER
Group type: OTHER
Intervention: para clinical data
Description: biological data, medical imaging data

Intervention type: OTHER
Group type: OTHER
Intervention: para clinical data
Description: biological data, medical imaging data

Intervention type: OTHER
Group type: OTHER
Intervention: Patient reported outcomes (PROs)
Description: Psoriatic arthritis impact of disease 12 (PsAID12), hospital anxiety and depression scale (HAD), SF 36
Study: NCT04431687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD 501
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D759, D150
Description: QD, PO
Study: NCT04325724

Intervention type: OTHER
Group type: OTHER
Intervention: Patient reported outcomes (PROs)
Description: Psoriatic arthritis impact of disease 12 (PsAID12), hospital anxiety and depression scale (HAD), SF 36

Intervention type: OTHER
Group type: OTHER
Intervention: Patient reported outcomes (PROs)
Description: Psoriatic arthritis impact of disease 12 (PsAID12), hospital anxiety and depression scale (HAD), SF 36

Intervention type: OTHER
Group type: OTHER
Intervention: Patient reported outcomes (PROs)
Description: Psoriatic arthritis impact of disease 12 (PsAID12), hospital anxiety and depression scale (HAD), SF 36
Study: NCT04006522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-Atezolizumab
Description: 89Zr-DFO-Atezolizumab infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-Atezolizumab
Description: 89Zr-DFO-Atezolizumab infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/Computed Tomography
Description: PET/CT scan 7 days (± 1 day) after infusion of 89Zr-DFO-Atezolizumab.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/Computed Tomography
Description: PET/CT scan 7 days (± 1 day) after infusion of 89Zr-DFO-Atezolizumab.
Study: NCT04836598

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: A Prospective randomized controlled trial study was undertaken along 4 years Between November 2016 and October 2020, in two institutions. 400 patients were selected, 200 patients underwent BLLC and 200 patients underwent multiple port laparoscopic cholecystectomy (MPLC).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: A Prospective randomized controlled trial study was undertaken along 4 years Between November 2016 and October 2020, in two institutions. 400 patients were selected, 200 patients underwent BLLC and 200 patients underwent multiple port laparoscopic cholecystectomy (MPLC).
Study: NCT00555139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK561679 tablet
Description: GSK561679 tablets are white film-coated tablets, containing 200 (milligrams) mg of the free base, GSK561679A.
Study: NCT02821559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOMOX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOMOX
Study: NCT00555139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW876008 tablet
Description: GW876008 tablets are white to off-white round film-coated tablets, containing 100 mg of GW876008X (free base).
Study: NCT03129022

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural anaesthesia
Description: Women requesting epidural analgesia received a bolus of intravenous infusion of lactated Ringer's solution before initiation of the procedure. An 18-gauge Tuohy needle and closed-tip clear catheter with three lateral orifices were used in the sitting or lateral position, with a loss-of-resistance to air technique. Epidural catheters were routinely inserted 5-6 cm inside the epidural space. A test dose of 2 ml of lidocaine 2% was initiated followed by a loading dose of 10 ml of bupivacaine 0.25%. Analgesia is maintained throughout labor using 0.125% bupivacaine with fentanyl 2 μg/ml with patient-controlled epidural analgesia by means of a continuous epidural infusion (8 ml/h basal rate) and patient-controlled boluses (3 ml each) with 20-minlock-out intervals
Study: NCT02821559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was allowed and used at 7,5 mg/kg or 5 mg/kg every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was allowed and used at 7,5 mg/kg or 5 mg/kg every 2 weeks.
Study: NCT03956875

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: yoga
Description: yoga is a mind-body practice that guides the body through a series of poses and breathing exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: yoga
Description: yoga is a mind-body practice that guides the body through a series of poses and breathing exercises
Study: NCT02413268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitroglycerin
Study: NCT03477981

Intervention type: OTHER
Group type: OTHER
Intervention: Alginate bread
Description: White bread with 4% alginate (wet weight of dough) included into the bread.
Study: NCT01757847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: The ACT group protocol consists of four 2-hour weekly sessions focusing on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief MOVE-II control group intervention
Description: The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition to reinforcing the strategies taught during MOVE! and to provide support in implementing those strategies, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism.
Study: NCT00154466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cardiac rehabilitation
Description: Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2); those in the nontraining group continued their usual lifestyle.
Study: NCT01484366

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intramedullary nailing and plating
Description: Surgical intramedullary nailing of the ulna and plating of the radius

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plating
Description: Surgical plating of both bonforearm fractures
Study: NCT04171076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation
Description: Theta burst stimulation at thoracic level (T5) over 2 minutes
Study: NCT00976898

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Irradiation
Description: Given once a day, 5 days a week, for 3 weeks
Study: NCT00523380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-21
Description: Administered i.v. in treatment cycles of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caelyx (pegylated liposomal doxorubicin)
Description: Administered i.v. in treatment cycles of 28 days.
Study: NCT00555139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam
Description: Alprazolam capsules 0.25 mg are hard gelatine capsules containing 1 tablet of commercial alprazolam (Xanax 0.25).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam
Description: Alprazolam capsules 0.25 mg are hard gelatine capsules containing 1 tablet of commercial alprazolam (Xanax 0.25).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GW876008 placebo tablets will visually match the active GW876008 tablets. GSK561679 placebo tablets will visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that will visually match the active but containing only a filler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GW876008 placebo tablets will visually match the active GW876008 tablets. GSK561679 placebo tablets will visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that will visually match the active but containing only a filler.
Study: NCT03657966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa
Description: activated dendritic cells (DCVAC/OvCa) for immune maintenance after chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy
Description: either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa
Study: NCT03691324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhalation technique training and discharge service
Description: Patient drug counselling one-to-one, focusing on inhalation drugs and technique
Study: NCT01702181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPA-15406
Description: 0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: 0.1% concentration of tacrolimus.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01501084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: 10mcg sc (subcutaneous) injection once at one of the 2 MRI visits

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline .2cc subcutaneous injection
Description: sterile saline injection
Study: NCT03419975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJO-002
Description: Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
Study: NCT00256282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 30 mg/m2 IV over 6-10 min every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 40mg/m2 IV over 1 hour every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: 250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days
Study: NCT01874990

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high sodium diet
Description: The high-sodium diet was obtained by adding 6g of sodium chloride to the individual's regular diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high sodium diet
Description: The high-sodium diet was obtained by adding 6g of sodium chloride to the individual's regular diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low-salt diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low-salt diet
Study: NCT02923544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: YUMI manipulator
Study: NCT04192162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mud therapy application
Description: Aplication the mud pack therapy from 20 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mud therapy application
Description: Aplication the mud pack therapy from 20 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sulfur water application
Description: Aplication the sulfur water in bath from 20 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sulfur water application
Description: Aplication the sulfur water in bath from 20 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hygienic water
Description: Exercise in hygienic water
Study: NCT02935517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGTC-402
Description: AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGTC-402
Description: AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGTC-402
Description: AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.
Study: NCT04431687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D759, D150
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D759, D150
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D759, D150
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D759, D150
Description: QD, PO
Study: NCT02935517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGTC-402
Description: AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGTC-402
Description: AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGTC-402
Description: AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGTC-402
Description: AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGTC-402
Description: AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.
Study: NCT01038817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duraphat
Description: After prophylactic cleaning of the mouth and teeth, application of fluoride varnish according to the manufacturer's recommendations (up to 0.75 ml per application)
Study: NCT04431687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D759, D150
Description: QD, PO
Study: NCT02788045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos.HIV
Description: Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Recombinant replication-deficient Ad26 vectored vaccine and consists of 4 Ad26 vectors, 2 containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5mL injection administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C gp140
Description: Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
Study: NCT03161717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural electrical stimulation (EES)
Description: Using loss of resistance technique and electrical stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Loss of resistance (LOR)
Description: Using loss of resistance technique only
Study: NCT00519194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epicor LP Cardiac Ablation System
Description: Surgical ablation of permanent AF during concomitant open chest and/or open heart surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical ablation of permanent AF
Description: Concomitant AF ablation during mitral valve surgery
Study: NCT02788045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C gp140
Description: Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 0.9 percent (%), 0.5 mL injection administered intramuscularly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 0.9 percent (%), 0.5 mL injection administered intramuscularly.
Study: NCT03601819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Patients will receive continuous treatment until progressive disease, toxicity, or until any other condition for treatment discontinuation has been met.
Study: NCT02177422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: telmisartan 80 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 12.5 mg or 25 mg Hydrochlorothiazide in addition to telmisartan in case that the goal response (mean sitting diastolic blood pressure \< 90 mmHg) is not met after at least 4 weeks of treatment with telmisartan
Study: NCT04511910

Intervention type: PROCEDURE
Intervention: Early Laparoscopic Cholecystectomy

Intervention type: PROCEDURE
Intervention: Early Laparoscopic Cholecystectomy

Intervention type: PROCEDURE
Intervention: Early Laparoscopic Cholecystectomy
Study: NCT02277847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin(8mg/m2) and cytosine arabinoside
Description: IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin(10mg/m2), cytosine arabinoside
Description: IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
Study: NCT04231422

Intervention type: COMBINATION_PRODUCT
Intervention: Platelet-rich plasma
Description: 12mL of platelet-rich plasma injected into cavernosal bodies bilaterally
Study: NCT03238781

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was presented in identical containers, stored/packaged the same as AMG 301. All injections were administered within 30 minutes on treatment days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 301
Description: AMG 301 was packaged in 5 mL clear glass vials containing 1 mL of 70 mg/mL of AMG 301. All injections were administered within 30 minutes on treatment days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 301
Description: AMG 301 was packaged in 5 mL clear glass vials containing 1 mL of 70 mg/mL of AMG 301. All injections were administered within 30 minutes on treatment days.
Study: NCT00624260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: semi-annual systematic PET-TDM
Description: semi-annual systematic PET-TDM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PET-TDM for current indication
Description: PET-TDM for current indication (high isolated markers or before a metastasis curative resection)